InsiderTrades

Form 4 for NTLA Intellia Therapeutics, Inc.

Accepted 2021-08-11 00:00:00 ET · period of report 2021-08-09 · accession 0001209191-21-050881 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-08-11 2021-08-09 NTLA Lebwohl David EVP, Chief Medical Off M - OptEx $12.62 +2,400 3,191 +303% +$30.3K
D 2021-08-11 2021-08-09 NTLA Lebwohl David EVP, Chief Medical Off S - Sale+OE $164.05 -2,400 791 -75% -$393.7K
D 2021-08-11 2021-08-09 NTLA Lebwohl David EVP, Chief Medical Off M - OptEx $0.00 -2,400 197.6K -1% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-08-09 M A 2,400 $12.62 3,191 D — —
2 Common Common Stock 2021-08-09 S D 2,400 $164.05 791 D — — (F2) Includes 568 and 223 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020 and June 30, 2021, respectively.
3 Derivative Stock Option (right to buy) 2021-08-09 M D 2,400 $0.00 197,600 D $12.62 · — to 2030-05-04 2,400 Common Stock (F3) The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 62,500 shares as of August 9, 2021.